The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in
the primary and secondary prevention of cardiovascular events. Although statin therapy is …

Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular
disease: each 1.0 mmol/L (38.7 mg/dL) reduction in LDL-C reduces the incidence of major …

Low‐density lipoprotein lowering with statins has convincingly and consistently proven to
reduce cardiovascular events in both primary and secondary prevention. However, despite …

Mammalian sterol and lipid metabolism depends on a large number of highly evolved
biochemical and histological processes responsible for the absorption, distribution and …

Ezetimibe, an inhibitor of intestinal cholesterol absorption, can decrease total cholesterol
(TC), low density lipoprotein cholesterol (LDL-C), triglycerides (TGs) and apolipoprotein …

Baylor University Medical Center Proceedings Volume 19, Number 1 74 that pertains to
medicine, consider the virtues of taciturnity. Look out. Speak only when you have something …

The primary aim of lipid-related cardiovascular disease (CVD) risk management is the
lowering of LDL-C levels. Numerous studies have shown that statins, which inhibit …

Ezetimibe/simvastatin combination, either as a single pill or as the combined use of the
individual compounds, represents a well-tolerated and efficacious choice for dyslipidemia …

Various guidelines for cholesterol management recognize LDL cholesterol (LDL‑C) lowering
as the primary target of lipid‑lowering therapy (LLT) and statin therapy as an important …

In numerous clinical trials, lowering LDL-C with statin therapy has been demonstrated to
reduce the risk of cardiovascular disease (CVD) in primary and secondary prevention …